John Wittman, MD
Neurology · Richmond, VANPI 1366412892
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Eisai Inc. at 30.1% of the total. Reporting peaked in 2019 at $14,093 and has fallen 70.1% since, to $4,218 in 2025. Among neurology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,123 payments — averaging $54.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$18K
- SK Life Science, Inc.$12K
- AbbVie$9K
- UCB, Inc.$4K
- Biogen$2K
- Ceribell, Inc.$1K
- plus $14K from 54 others
Across 4 payments — averaging $3461.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$14K
What the payments were for
- Consulting fees$2,1303%
- Speaking & faculty fees$30,94851%
- Travel & lodging$3,6906%
- Food & beverage$24,06939%
- Education$4291%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$61,266 in reported general payments places this provider in the 90th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FinteplaFenfluramine Hcl | 23 | $393,718 |
| WakixPitolisant Hcl | 14 | $221,395 |
| BriviactBrivaracetam | 117 | $181,417 |
| XcopriCenobamate | 90 | $180,167 |
| EpidiolexCannabidiol (Cbd) | 37 | $168,393 |
| AptiomEslicarbazepine Acetate | 78 | $142,369 |
| CopaxoneGlatiramer Acetate | 13 | $74,599 |
| Rufinamide | 31 | $67,687 |
| FycompaPerampanel | 45 | $59,307 |
| VimpatLacosamide | 38 | $50,858 |
| Lamictal XrLamotrigine | 25 | $43,686 |
| KeppraLevetiracetam | 19 | $31,487 |
| Lacosamide | 244 | $31,469 |
| Lamotrigine ErLamotrigine | 65 | $23,046 |
| BanzelRufinamide | 13 | $22,562 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Fintepla, Briviact, Vimpat, Nayzilam | $3,917 | $647,758197 claims |
| Harmony Biosciences LLCWakix | $326 | $221,39514 claims |
| SK Life Science, Inc.Xcopri | $12,158 | $180,16790 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $963 | $142,36978 claims |
| Eisai Inc.Fycompa, Banzel | $18,447 | $81,86958 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $387 | $74,59913 claims |
| PfizerNurtec Odt, Dilantin | $310 | $31,40156 claims |
| Neurelis, Inc.Valtoco | $629 | $20,59919 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $430 | $4,07121 claims |
| Upsher-smith Laboratories LLCTopiramate | $41 | $3,237149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 474 neurology providers in Virginia.
Other neurology in Richmond
- Catherine HamRichmond$603K
- Daniel HardyRichmond$382K
- Myla GoldmanRichmond$132K
- Alan SchulmanRichmond$104K
- Warren FeltonRichmond$96K
- Matthew BoyceRichmond$56K
- Leslie CloudRichmond$46K
- Jonathan BekensteinRichmond$37K
- Jessica LehositRichmond$35K
- Claudia TestaRichmond$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.